Introduction: This study focuses on the treatment of painful crises in Sickle Cell Disease (SCD) patients using Paracoxib, a non-opioid, compared to Morphine. It addresses the need for alternative medications that reduce opioid dependency while providing effective analgesia.
Objectives:
Primary: Evaluate the analgesic effect of Paracoxib versus Morphine in SCD vaso-occlusive crises.
Secondary: Reduce opioid use/dependence, decrease the length of hospital stays, and monitor side effects related to Paracoxib.
Methodology: A double-blinded randomized controlled trial, conducted in a tertiary care emergency department. The study includes adult SCD patients with moderate to severe crises, excluding non-VOC pain, certain medications, and specific medical conditions. The sample size is 226 patients, split equally into two groups.
Intervention: Patients receive either Morphine or Paracoxib, with periodic assessment of vital signs and pain. Additional Morphine is administered if required. Data collection and analysis are meticulously planned.
Expected Outcomes: Improvement in SCD pain management, reduction in opioid usage, and potential benefits in terms of hospital stays and patient satisfaction.

开始日期2026-05-01

申办/合作机构

Armed Forces Hospital

ChiCTR2500095107

/ SuspendedN/AIIT

Effect of esketamine combined with parecoxib sodium on postoperative analgesia and inflammatory response in patients with thoracoscopic pulmonary resection

开始日期2025-01-05

申办/合作机构-

NCT06721988

/ Not yet recruitingN/AIIT

Exploring the Effect of Preventive Analgesia with Oxycodone and Parecoxib Sodium on the Chronification of Acute Pain in Adult Patients Underwent Laparoscopic-assisted Abdominal Major Surgery

The goal of this clinical trial is to learn if the administration of oxycodone for preventive analgesia works to reduce the chronification of acute postoperative pain in adult participants undergoing major abdominal surgery. The main question it aims to answer is:
• Does administration of oxycodone before surgical incision reduce the occurrence of chronic pain or relieve the chronic pain symptoms 3 months after the operation? Researchers will compare oxycodone + parecoxib sodium to placebo + parecoxib sodium combinations to see if oxycodone works to reduce the chronification of acute postoperative pain.
Participants will:
* Take oxycodone + parecoxib sodium or placebo + parecoxib sodium combinations before the surgical incision
* Cooperate with the follow-up staffs and complete some checkups or tests within 3 months after the operation.

开始日期2025-01-01

申办/合作机构

华中科技大学同济医学院附属同济医院

[+2]

100 项与帕瑞昔布钠相关的临床结果

登录后查看更多信息

100 项与帕瑞昔布钠相关的转化医学

登录后查看更多信息

100 项与帕瑞昔布钠相关的专利（医药）

登录后查看更多信息

1,298

项与帕瑞昔布钠相关的文献（医药）

2025-01-24·Journal of Burn Care & Research

Effects of Parecoxib Sodium on Early Cognitive Impairment and Inflammation Levels in Burned Rats

Article

作者: Hu, Guangjun ; Jiang, Xiaoyang ; Zhang, Kun ; Du, Siyu ; Chen, Zhuo

Abstract:

To study the effect of parecoxib sodium in alleviating inflammation in burned rats and restoring cognitive function in burned rats. A total of 30 specific pathogen free grade Sprague–Dawley rats were randomly divided into 6 groups: (1) blank control group (group C), (2) Sham surgery group (group Sham), (3) second-degree burn model (group B), (4) low-dose (1 mg/kg/d) parecoxib sodium (group L + B), (5) medium-dose (10 mg/kg/d) parecoxib sodium (group M + B), and (6) high-dose (20 mg/kg/d) parecoxib sodium (group H + B). ELISA measures inflammatory factors interleukin (IL)-2, IL-6, tumor necrosis factor-alpha (TNF-α), and interferon-gamma (IFN-γ), and cognitive function factors neuron-specific enolase (NSE), cortisol, and S-100β. Combined with water maze and dark-avoidance experiments to further verify the recovery of cognitive function in rats. The contents of IL-2, TNF-α, and IL-6 in group M + B were significantly lower than those in group Sham (P < .05), and the content of IFN-γ was significantly lower than that in group Sham (P < .05). The cognitive markers NSE, S-100β, and cortisol levels in group M + B were significantly higher than those in group Sham at 2 h, 1 d, 5 d, and 10 d after operation (P < .05). In the group M + B dark-avoidance experiment, the number of probes and errors was not significantly different than those in group Sham and group C (P > .05), and the number of times group M + B found a platform in the water maze experiment and crossed the platform was second only to group B and group C. Parecoxib sodium can effectively reduce inflammation in burn rats and promote cognitive recovery in burn rats, and the optimal dose of parecoxib sodium for burn rats is 10 mg/kg.

2024-12-31·International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group

Risk factors of chronic kidney disease in cisplatin-based hyperthermia intraperitoneal chemotherapy

Article

作者: Cheng, Chih-Chung ; Yeh, Hung-Chieh ; Chang, Sheng-Chi ; Ho, Chien-Lin ; Su, Pei-Wen

PURPOSE:

Cisplatin is commonly prescribed in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancy. Acute kidney injury (AKI) is regarded as a common complication after HIPEC combined with cytoreductive surgery (CRS). However, post-HIPEC chronic kidney disease (CKD) is scarce and less investigated. This study aims to investigate the incidence of CKD following cisplatin-based HIPEC and to analyse the associated risk factors.

MATERIALS AND METHODS:

From January 2016 to August 2021, a total of 55 patients treated with CRS and cisplatin-based HIPEC for peritoneal carcinomatosis were categorized retrospectively into groups, with and without CKD. Demographics, comorbidity, surgery, postoperative management, and complications were collected to evaluate risk factors for cisplatin-based HIPEC-related CKD. Univariate and multivariate analyses were conducted to confirm the correlation between different variables and CKD occurrence.

RESULTS:

Of the 55 patients, 24 (43.6%) patients developed AKI and 17 (70.8%) patients of these AKI patients progressed to CKD. Multivariate regression analysis identified intraoperative use of parecoxib (Odds Ratio (OR) = 4.39) and intraoperative maximum temperature > 38.5°C (OR = 6.40) as major risk factors for cisplatin-based HIPEC-related CKD occurrence. Though type II diabetes mellitus and intraoperative complications were the independent risk factors of AKI following cisplatin-based HIPEC, but they were not shown in CKD analysis.

CONCLUSION:

Intraoperative use of parecoxib during cisplatin-based HIPEC emerged as a significant risk factor for postoperative CKD. Clinicians should exercise caution in prescribing parecoxib during HIPEC procedures. Additionally, maintaining intraoperative body temperature below 38.5°C might be crucial to mitigate the risk of CKD development. This study underscores the importance of identifying and preventing specific risk factors to improve long-term renal outcomes in patients undergoing cisplatin-based HIPEC.

2024-12-01·NEUROPHARMACOLOGY

Increased levels of Escherichia-Shigella and Klebsiella in the gut contribute to the responsivity of placebo analgesia

Article

作者: Liu, Cunming ; Zhang, Xinying ; Hu, Suwan ; Zhang, Qi ; Yang, Chun ; Bu, Yuchen ; Wu, Zifeng ; Wang, Di ; Yang, Siqi ; Wang, Yuanyuan ; Huang, Chaoli

Placebo analgesia is observed in both humans and animals. Given the complexity of placebo analgesia involving a variety of neurobiological, psychological, and psychosocial processes, further investigation into its underlying mechanisms is essential. Gut microbiota has been implicated in the responsivity of placebo analgesia, but its precise role remains unknown and warrants further investigations. Here, we conducted a conditioning training model with chronic inflammatory pain induced by complete Freund's adjuvant (CFA) in mice, associating parecoxib with different cues. Hierarchical clustering analysis of placebo analgesia behaviors was employed to classify mice into responders and non-responders phenotypes. Approximately 40% of CFA mice undergoing conditioning training exhibited placebo analgesia. Notably, placebo analgesia responders displayed reduced anxiety-like behaviors. 16S rRNA results revealed a distinct composition of gut microbiota composition among the control, placebo analgesia non-responders and responders groups. Notably, levels of Escherichia Shigella and Klebsiella in the gut were increased considerably in the placebo analgesia responders as compared to both control and non-responders groups. In conclusion, placebo analgesia responders demonstrated marked analgesia, reduced anxiety-like behaviors, and increased levels of Escherichia-Shigella and Klebsiella, implying a potential linkage between gut microbiota and placebo analgesia.

项与帕瑞昔布钠相关的新闻（医药）

2025-03-24

·思齐俱乐部

业绩频频变脸，这家药企濒临退市

多个品种被集采，缺乏后继产品，这家药企或面临退市。业绩"变脸" 两个月内由盈转亏 3月15日，赛隆药业发布《关于公司股票交易可能被实施退市风险警示的提示性公告》。经赛隆药业财务部门初步测算，预计其2024年度扣除非经常性损益后的净利润为亏损2200万元-4200万元，扣除后营业收入为2.3亿元–2.5亿元。赛隆药业是一家集医药中间体、原料药、制剂的研发、生产、营销和技术服务为一体的医药全产业链的现代化制药企业，注射剂和原料药是其主要产品，拥有包括注射用艾司奥美拉唑钠、门冬氨酸鸟氨酸注射液、注射用帕瑞昔布钠、注射用胸腺法新、阿加曲班注射液等。 1月22日，赛隆药业发布2024年业绩预告称，预计2024年归母净利润盈利450万元-650万元；扣非净利润盈利420万元-620万元。不到两个月的时间，赛隆药业的业绩“由预盈转为预亏”。根据《深圳证券交易所股票上市规则》第9.3.1条第（一）项规定，在披露2024年年度报告后，赛隆药业股票交易可能被深圳证券交易所实施退市风险警示（股票简称前冠以“*ST”字样）。赛隆药业称，业绩修正主要有两个原因，一是其与年审会计师深入沟通后，结合业务实际情况，对部分销售收入确认进行再次分析，基于谨慎性原则，部分收入2024年度不予确认。预计减少收入约3963.25万元，减少毛利约3395.71万元；二是在资产减值方面，其针对部分闲置的固定资产进行减值测试，预计将补充计提资产减值准备200-450万元。赛隆药业在1月份的业绩预告中称，扣非净利润的增长主要是其报告期内合理控制各项费用支出。值得注意的是，控费带来的盈利可持续性具有较大的不确定性。多次修正业绩预告此前曾收监管函这已经不是赛隆药业第一次修正业绩预报，此前，赛隆药业对2022年业绩预告进行修正，归母净利润由亏损1500万元-2500万元，修正为亏损3500万元-4600万元。修正的原因是，增加信用减值损失计提约600万元；调增当期收入对应的成本费用约200万元；补提资产减值损失约400万元。深交所还曾发布监管函指出，赛隆药业预告披露的预计净利润与年度报告披露的经审计净利润相比，差异幅度较大且未及时修正。从赛隆药业的发展来看，2020年-2022年连连亏损，净利润分别是-6722.19万元、-2334.14万元、-3731.23万元。2023年赛隆药业的业绩有所回暖，净利润达到953.37万元，同比增长125.55%。不过，如果2024年业绩发布，赛隆药业净利润为亏本，仍有被*ST的风险。仿制药集采承压缺乏原研产品成硬伤截至2024年上半年，赛隆药业主要生产、销售及拥有生产批文的原料药品种13个，制剂品种17个，其中11个品种通过仿制药一致性评价，16个品种被列入《国家基本医疗保险、工伤保险和生育保险药品目录（2023版）》。赛隆药业的产品均为仿制药，且处方药居多，院内市场是发展主力“战场”。随着集采的深入推进，其已经有多个产品被纳入，业绩承压。照片来源：同花顺如阿加曲班注射液、氨甲环酸注射液两个品种三个规格中标第八批国采；注射用奥美拉唑钠、米力农注射液和注射用替加环素等三个品种四个规格中标第七批国采；门冬氨酸鸟氨酸中标云南、北京地方集采；赖氨匹林中标江苏地方集采等。赛隆药业称，要继续积极参与国家、省级联盟等各类集采，进一步优化营销中心组织架构，突出重点品种的销售占比及毛利贡献，促进销售指标达成。在第十批国采中，湖南赛隆药业(长沙)的盐酸艾司洛尔注射液、氟尿嘧啶注射液中标，4月第十批国采就将执行，以价换量之下，最终对业绩的影响仍不确定。严格强制退市标准业绩差公司首当其冲梳理发现，目前已经有不少药企股票触及终止上市的情形，包括*ST吉药、*ST大药等。中国证监会发布《关于严格执行退市制度的意见》提出，进一步严格强制退市标准。加大绩差公司退市力度，提高亏损公司的营业收入退市指标，淘汰缺乏持续经营能力的公司；完善市值标准等交易类退市指标。一般来看，药企股票触及终止上市的情形可能有：财务指标不达标：连续亏损或净资产持续为负；股价长期低于面值或交易所规定的最低标准；涉及财务造假、信息披露违规等行为；药企进入破产或清算程序；药企可能因私有化、并购等原因主动申请退市。财务状况不佳是很多药企触发退市风险的主要问题，回到赛隆药业，后续如何扭亏并改善经营是关键。来源：赛柏蓝作者：颜色点击阅读原文了解更多

财报

2025-03-24

·米内网

【重磅】13亿大品种！扬子江获批了

精彩内容近日，NMPA官网显示，扬子江药业以仿制4类报产的艾拉莫德片获批上市，为国内第2家仿制+第2家过评。艾拉莫德片为风湿科常用药，2023年在中国三大终端六大市场销售额超过13亿元。艾拉莫德是一种新型的改善病情抗风湿病药物，具有抗炎、抑制免疫球蛋白生成、抑制炎性因子产生、抗骨吸入和促骨形成等作用。米内网数据显示，2023年中国三大终端六大市场（统计范围详见本文末）艾拉莫德片销售额超过13亿元，同比增长18.60%；2024年上半年其销售额超过9亿元，同比增长29.65%。中国三大终端六大市场艾拉莫德片销售情况（单位：万元）来源：米内网格局数据库艾拉莫德片是由先声药业研发的国产新药，于2011年获批上市，正大清江于2024年6月拿下该品种国内首仿+首家过评，此次扬子江药业的艾拉莫德片获批上市，为国内第2家仿制+第2家过评。在抗炎药和抗风湿药领域，目前扬子江药业已有8个品种获批上市，包括艾拉莫德片、美洛昔康片、注射用帕瑞昔布钠、塞来昔布胶囊、依托考昔片、萘普生缓释片、双氯芬酸钾片等。资料来源：米内网数据库、NMPA 注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

上市批准

2025-03-06

·米内网

【首仿】大涨117%潜力品种，一品红出击

精彩内容近日，CDE官网显示，广州市联瑞制药/重庆博腾药业的4类仿制药硫酸艾沙康唑胶囊提交上市申请并获受理。这是一款广谱的三唑类抗真菌药，在国内暂无仿制药获批，原研产品2024上半年在中国三大终端六大市场（统计范围详见本文末）的销售额增速约达117%。硫酸艾沙康唑胶囊是辉瑞开发的一款广谱三唑类抗真菌药物，主要用于治疗18周岁以上患者的侵袭性曲霉菌感染和侵袭性毛霉菌感染。米内网数据显示，硫酸艾沙康唑胶囊已被纳入国家医保乙类目录，近年来在中国三大终端六大市场快速放量，2023年其销售额增速约196%，2024上半年以约117%的增速继续增长，销售额已超2023年全年水平。近年来中国三大终端六大市场硫酸艾沙康唑胶囊销售情况（单位：万元）来源：米内网格局数据库国内暂无硫酸艾沙康唑胶囊仿制药获批，目前已有5家药企的产品以新注册分类报产，包括杭州沐源生物、江西艾施特制药、重庆希韦医药、奥赛康及广州联瑞制药，首仿花落谁家？我们拭目以待。硫酸艾沙康唑胶囊仿制药申报情况来源：米内网中国申报进度（MED）数据库 2025年至今，一品红有盐酸丙卡特罗口服溶液、苯溴马隆片、注射用帕瑞昔布钠、复方聚乙二醇(3350)电解质口服溶液、硫酸艾沙康唑胶囊5个品种以新注册分类报产，甲钴胺注射液、苯磺酸氨氯地平片2个品种获批生产并视同过评。资料来源：米内网数据库、CDE官网等注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至3月6日，如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

上市批准一致性评价

100 项与帕瑞昔布钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D03717	帕瑞昔布钠	M01AH04	DB08439

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
术后疼痛	欧盟	Pfizer Europe MA EEIG	2002-03-22
术后疼痛	冰岛	Pfizer Europe MA EEIG	2002-03-22
术后疼痛	列支敦士登	Pfizer Europe MA EEIG	2002-03-22
术后疼痛	挪威	Pfizer Europe MA EEIG	2002-03-22

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
疼痛	临床3期	澳大利亚	Pfizer Inc.	2003-04-01
绞痛	临床3期	意大利	Pfizer Inc.	2002-04-01
肾绞痛	临床3期	意大利	Pfizer Inc.	2002-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ILCA2020	临床3期	肝细胞癌	80	Parecoxib sodium 40 mg	夢窪鹹範製齋觸夢構膚(鑰窪淵鹽衊鑰膚簾願艱) = 構襯鏇糧製膚構積襯鏇淵醖鏇鹽廠獵窪顧壓醖 (齋襯繭壓簾襯獵範齋淵, 9.8 ~ 28.2) 更多	积极	2020-09-13
				Placebo	夢窪鹹範製齋觸夢構膚(鑰窪淵鹽衊鑰膚簾願艱) = 襯醖衊範膚築獵積範願淵醖鏇鹽廠獵窪顧壓醖 (齋襯繭壓簾襯獵範齋淵, 8.1 ~ 19.9) 更多
ILCA2020	N/A	肝细胞癌	-	Parecoxib sodium + TAP block	廠製鹹壓夢餘襯襯遞廠(蓋鏇糧構憲鏇願鹹構簾) = No significant differences were found between the two groups related to adverse events 簾觸齋壓廠鬱蓋積積艱 (繭願襯觸獵憲廠襯願艱 ) 更多	积极	2020-09-13
NCT01566669 (PCEA, Pubmed \| PLoS One)	N/A	-	240	Parecoxib	鹹鑰醖築鑰簾蓋艱膚願(觸網積願繭餘鹹範憲鹽) = 衊選鏇鹹願鏇築廠膚遞積鹹鏇積鏇顧構糧糧願 (選蓋鹹製築夢鏇繭築襯 ) 更多	积极	2016-01-01
				Placebo	鹹鑰醖築鑰簾蓋艱膚願(觸網積願繭餘鹹範憲鹽) = 範鏇窪醖製構醖蓋選範積鹹鏇積鏇顧構糧糧願 (選蓋鹹製築夢鏇繭築襯 ) 更多
NCT00346268 (PROSTATECTOMY, Pubmed \| BMC Anesthesiol) 人工标引	临床4期	出血 \| 镇痛	105	Morphine+parecoxib	淵鹹製艱構觸觸艱餘鹽(鹹衊鏇鑰築壓鹽鹹範製) = 構醖積獵網窪窪築鹽鑰艱構憲鑰積範膚積蓋醖 (衊艱簾鬱範鑰鑰獵糧獵, 24.1) 更多	积极	2015-03-09
				Morphine+Placebo	淵鹹製艱構觸觸艱餘鹽(鹹衊鏇鑰築壓鹽鹹範製) = 醖齋構顧遞鑰艱構構繭艱構憲鑰積範膚積蓋醖 (衊艱簾鬱範鑰鑰獵糧獵, 28) 更多
NCT00553605 (NAP, CTgov)	临床4期	肾绞痛	340	Parecoxib (Parecoxib)	鹹簾鹹願糧夢繭範襯遞(鏇衊鹹壓醖壓蓋範鑰蓋) = 窪積範壓願鏇窪淵選餘蓋艱鬱積範鹽範衊製鏇 (願製願遞構膚願壓淵顧, 3.35) 更多	-	2013-01-28
				Ketoprofen (Ketoprofen)	鹹簾鹹願糧夢繭範襯遞(鏇衊鹹壓醖壓蓋範鑰蓋) = 齋鏇膚鏇憲淵鹹壓衊鹽蓋艱鬱積範鹽範衊製鏇 (願製願遞構膚願壓淵顧, 3.46) 更多
NCT00346268 (PROSTATECTOMY, CTgov)	临床4期	术后疼痛	105	Parecoxib+Morphine (Parecoxib and Morphine)	醖範艱獵醖觸鬱顧齋齋(夢壓餘淵製顧獵鑰鹽繭) = 壓選鹹艱艱獵廠構襯蓋艱膚艱膚衊網糧積艱淵 (鹹醖鏇糧網遞膚製廠醖, 16.16) 更多	-	2011-10-28
				Placebo+Morphine (Placebo and Morphine)	醖範艱獵醖觸鬱顧齋齋(夢壓餘淵製顧獵鑰鹽繭) = 襯範鑰網鹽獵鏇糧製顧艱膚艱膚衊網糧積艱淵 (鹹醖鏇糧網遞膚製廠醖, 19.99) 更多
NCT00455117 (Pubmed \| Br J Anaesth)	临床4期	术后疼痛	-	Parecoxib 40 mg	構積廠膚獵獵鏇觸窪醖(窪憲鹽繭鏇醖艱夢淵襯) = 夢艱網齋窪遞鑰壓廠鏇築廠觸艱糧顧襯蓋衊製 (鏇築夢夢顧衊憲糧窪顧 )	不佳	2011-09-01
				Placebo	構積廠膚獵獵鏇觸窪醖(窪憲鹽繭鏇醖艱夢淵襯) = 網醖淵艱網膚簾鑰鑰窪築廠觸艱糧顧襯蓋衊製 (鏇築夢夢顧衊憲糧窪顧 )